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The prion protein (PrP) has been extensively studied because of its central role in a group of
neurodegenerative conditions collectively known as prion diseases. While a wealth of informa-
tion is available for the pathology and transmission of these diseases, the molecular mecha-
nisms involved are not yet clearly defined.
So, how do we learn about the molecular mechanisms underlying the pathogenic role of the
PrP in disease? What have we learned about the physiological role of the PrP? Defining PrP
function may shed light on pathological processes involved in prion diseases. The PrP has
been shown to participate in several biological processes, including neuritogenesis, neuronal
homeostasis, cell signalling, cell adhesion, and a protective role against stress. This pleiotrop-
ism has led to confusion about the precise molecular function(s) of the PrP. This essay shall
attempt to clarify the most relevant physiological roles of the protein in the context of the cen-
tral and peripheral nervous system.
The PrP
The PrP can exist in 2 distinct conformations: the host-encoded, physiological cellular prion
protein (PrPC) and the pathogenic isoform denoted as prion (usually referred to as PrPSc). The
latter plays a key role in the pathological outcome of prion diseases, while the former is a ubiq-
uitous protein expressed in most cell types in mammals.
The PrPC is encoded by the Prnp gene located on chromosome 20 in humans (PRNP) and
chromosome 2 in mice. Depending on the species considered, the Prnp gene contains either 2
or 3 exons, with the entire coding region being contained in the last exon, thus excluding pos-
sible alternative splicing [1].
The murine PrPC is a protein of about 254 amino acids prior to post-translational modifica-
tions and in its mature form is a 208–amino acid polypeptide, which is glycosylphosphatidyli-
nositol (GPI) anchored to the outer leaflet of the cellular membrane with a unique primary
sequence.
The unstructured N-terminal domain possesses distinctive sequences identified as octare-
peats, solely represented in PrPC, which are unique among all proteins. These octarepeat
regions, with a consensus sequence of PHGGGWGQ, contain hystidine residues able to bind
monovalent and divalent cations, such as copper ions Cu+ and Cu2+. The octarepeat sequence
of the PrP binds Cu2+ with distinct coordination modes [2].
On the other end, the protein presents a well-structured C-terminal domain structurally
conserved in all mammals. The C-terminus contains a single disulphide bridge and 2 glycosyl-
ation sites. The asparagine residues involved in the glycosylation of the protein provide the
presence of 4 different isoforms of the protein; they could be both occupied by glycans or,
alternatively, only 1 could be glycosylated or none at all. The overall structure of the C-termi-
nus is composed of 2 short antiparallel beta sheet strands and 3 alpha helices, which provide a
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compact conformation retained in all mammalian species. More recently, a third beta sheet
strand has been identified, which may play a role in prion conversion (Fig 1) [3].
Via additional post-translation modifications, PrPC may be subjected to proteolytic pro-
cessing. One of the cleavage sites is present in the central region of the protein and produces
the N-terminal N1 soluble fragment and the GPI-anchored C-terminal C1 fragment. PrPC
may also be present as a soluble full-length isoform, resulting either from a phospholipase
cleavage of the GPI anchor or from proteolytic processing at the C-terminus. These varieties of
post-translational modifications can give rise to several different isoforms and this could ham-
per efforts on defining PrPC function(s) [4].
Lessons learned from knockout mouse models
With the exception of 3 PrP knockout mouse models, in which ectopic expression in the
central nervous system of the PrP paralogue Doppel leads to loss of Purkinje cells in the
cerebellum, the evidence that most mouse models’ knockout for the PrP do not show gross
abnormalities indicates that PrPC may be dispensable for embryonic development and adult-
hood. Nevertheless, several mouse models in which the Prnp gene is disrupted have been
Fig 1. Schematic representation of cellular prion protein (PrPC). The N-terminal domain of PrPC is unstructured and possesses distinctive
sequences identified as octapeptide repeats (see main text for details). These octarepeat regions contain hystidine residues (in blue) able to bind
monovalent and divalent cations, such as copper ions Cu+ and Cu2+ (orange dots). The C-terminus contains a single disulphide bridge (in red) and
2 glycosylation sites. The asparagine residues involved in the glycosylation of the protein are represented in green. The overall structure of the C-
terminus is composed of 2 short antiparallel beta sheet strands, namely β1 and β2 (in yellow) and 3 alpha helices, indicated as α1, α2, and α3. A
third beta sheet strand has been recently identified and named β0 (in yellow).
https://doi.org/10.1371/journal.ppat.1006458.g001
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developed [5]. Early studies using these models have implicated PrPC in circadian rhythms
and sleep dysfunctions [6], altered olfactory behavior [7], neuritogenesis and neural stem/pre-
cursor cells differentiation in the central nervous system [8], and myelination of neurons in
the peripheral nervous system [9].
In addition, more recent work has characterized PrPC involvement in synaptic plasticity
and N-methyl-d-aspartate receptors (NMDARs) regulation [10, 11].
Overall, these knockout models have been instrumental for defining PrPC function and
despite their limitations, they are still used in characterizing PrPC physiological roles in the
central and peripheral nervous system.
The function(s) of the PrP
One of the most intriguing function(s) of PrPC is its involvement in cell signalling. Because
of its extracellular localization, the protein could mediate environmental molecular signals to
the cell. Transduction of the signals cannot be mediated directly by PrPC because it is GPI
anchored to the cellular membrane without direct access to the cytosol but would require
interactions with other transmembrane proteins.
Perhaps the most important study and the first evidence that PrPC may be involved in
mediating extracellular signals is the description of a caveolin-1-dependent coupling of PrPC
to the proto-oncogene tyrosine-protein kinase Fyn (Fyn) [12]. Since this seminal work, it
became clear that PrPC could exert its function by partnering with other membrane proteins
to convey cellular signalling. The neural cell adhesion molecule (NCAM) was identified as one
preferential interactor of PrPC [13]. Through physical interaction with NCAM, PrPC can pro-
mote neuritogenesis via the tyrosine kinase Fyn [14–17]. In this work, the N-terminal domain
of PrPC is essential for regulating the neurite outgrowth and guidance function, indicating that
the N-terminus of the protein, which includes the octarepeats region, is essential for its func-
tion [17]. Notably, a soluble form of full-length PrPC has been used for focal stimulation of
neurite outgrowth and guidance [17].
In addition, in another work it has been shown that PrPC plays a critical role in NCAM-
dependent neuronal differentiation of neural stem/precursor cells [18].
PrPC is developmentally regulated and its high expression in the immature brain could be
relevant in regulating neurogenesis and cell proliferation [19]. A recent study shows that PrPC
plays a crucial role in regulating via protein kinase A (PKA) synaptic plasticity in the develop-
ing hippocampus, therefore contributing to proper synaptic formation in adulthood [10].
An important function linked to PrPC expression is its involvement in myelin formation
and maintenance. Aging PrP knockout mice present a clear phenotype in which the peripheral
nervous system shows demyelinating disease [9]. Molecular studies have shown that the N-ter-
minus of PrPC acts as an agonistic ligand of the adhesion G-protein coupled receptor G6
(Adgrg6) receptor, the function of which is critical for myelin maintenance [20].
PrP regulates NMDAR
One of the most detailed functional studies recently published deals with the involvement of
the cellular form of the prion protein PrPC and copper ions in NMDAR S-nitrosylation and
activity. By exploiting PrP knockout mice, the authors showed that the depletion of PrPC is
associated with a reduction in the S-nitrosylation of the 2 NMDAR subunits GluN2A and
GluN1, while not affecting the levels of the corresponding proteins at the synapse. The sensitiv-
ity of PrP knockout versus wild-type organotypic hippocampal cultures to N-methyl-d-aspar-
tate (NMDA)-mediated excitotoxicity was monitored under a great variety of conditions
that were selected in order to assess the involvement of calcium, copper, nitric oxide (NO),
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NMDA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainite, or
GluN2B receptors. These experiments unambiguously highlight a higher sensitivity of PrP
knockout mouse cultures to NMDA-mediated excitotoxicity, which can be reversed upon
exposure to the NO donor S-nitrosoglutathione (GSNO). Conversely, the results substantiate
an increased sensitivity of wild-type cultures to NMDA-dependent excitotoxicity when copper
or NO is chelated.
Fig 2. Schematic representation of the mechanism of cellular prion protein (PrPC)-mediated S-nitrosylation of N-
methyl-d-aspartate receptor (NMDAR). One mechanism controlling NMDAR as well as other membrane ion channels
involves direct modulation by nitric oxide (NO). Catalytic amounts of copper can act as electron acceptors promoting the
reaction of NO with thiols, providing inhibitory S-nitrosylation (RSNO) of NMDAR. The RSNO formation can take place only
after one-electron oxidation from the free radical NO to NO+ by transition metal. In brief, glutamate is released from the
presynaptic terminal of neurons and activates NMDAR on the postsynaptic terminal. NMDAR activation and opening generates
Na+ and Ca2+ influx and K+ efflux. In the cytosol, upon entrance, Ca2+ ions bind to different proteins, among these, calmodulin
(CaM). The CaM bound to Ca2+ triggers neuronal nitric oxide synthase (nNOS) and copper-transporting ATPase 1 (Atp7a).
Activation of nNOS leads to NO release in the synaptic cleft. Activation of Atp7a in the trans-Golgi network (TGN) ensues in Cu2+
release in the synaptic space. Transient free Cu2+ ions are immediately bound by copper-binding proteins like PrPC, which is
highly expressed in both pre- and postsynaptic terminals. PrPC has high affinity for both Cu2+ and Cu+ and can be found in lipid
raft domains, which also contain NMDAR. NO can react with extracellular cysteine thiols of NMDAR subunits GluN1 and GluN2A,
leading to cysteine S-nitrosylation (SNO-Cys). The S-nitrosylation inhibits NMDAR activation by closing the channel. The
chemical reaction between NO and cysteine thiol requires the presence of an electron acceptor such as Cu2+. PrPC coordinates
Cu2+ ions, which support the reaction of NO with thiols, leading to the S-nitrosylation of GluN1 and GluN2A and therefore NMDAR
inhibition.
https://doi.org/10.1371/journal.ppat.1006458.g002
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The molecular mechanism by which PrPC acts to regulate NMDAR S-nitrosylation regula-
tion can be summarized as follows. Upon glutamate release from the presynaptic terminal,
NMDARs are activated on the postsynaptic terminal, leading to calcium entry. Via a series of
molecular mechanisms, NO and copper ions are released in the synaptic cleft. Released Cu2+
ions are rapidly bound by copper-binding proteins including PrPC, which is highly expressed
in both presynaptic and postsynaptic terminals. PrPC has high affinity for both Cu2+ and Cu+
and it may reside in lipid raft domains, which also contain NMDAR. Synaptic NO can react
with extracellular cysteine thiols of NMDAR subunits GluN1 and GluN2A, leading to cysteine
S-nitrosylation. The S-nitrosylation inhibits NMDAR activation by closing the channel. The
chemical reaction between NO and cysteine thiol requires the presence of an electron acceptor
such as Cu2+. According to this model, PrPC positions Cu2+ ions that support the reaction of
NO with thiols, leading to the S-nitrosylation of GluN1 and GluN2A, thus inhibiting NMDAR
[11, 21] (Fig 2).
Future directions
In recent years, several function(s) of PrPC have been identified. The use of PrP knockout
mouse models has been influential for studying and clarifying the molecular mechanisms in
which the protein is involved. By learning the physiological function(s) of PrPC, our under-
standing of the neuropathological processes underlying prion diseases may progress towards
the development of novel therapeutic approaches to such devastating disorders [22].
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